Beyond Warburg: Jane McLelland’s Powerful Critique of Tom Seyfried’s Metabolic Theory of Cancer – What Patients Need to Know in 2026

By Editorial Team

Introduction: Why This Debate Matters Right Now

The metabolic theory of cancer is exploding in popularity. Professor Tom Seyfried has become a household name among patients seeking alternatives to conventional oncology, thanks to his groundbreaking book Cancer as a Metabolic Disease and the press-pulse strategy built around glucose and glutamine restriction.

But in May 2026, Jane McLelland—bestselling author of How to Starve Cancer and a stage 4 cancer survivor who reversed her own disease—published a must-read Substack titled “Beyond Warburg: What Tom Seyfried Gets Right — And the Blind Spot That Could Cost Your Patient.”

This isn’t a takedown. It’s a respectful, evidence-based extension that could save lives by highlighting a critical limitation in the “keto-for-everyone” approach. If you’re exploring ketogenic diet cancer protocols, repurposed drugs, or metabolic therapies, this article breaks it all down with actionable insights into the metabolic theory of cancer.

What Is Tom Seyfried’s Metabolic Theory of Cancer?

Seyfried revives and expands Otto Warburg’s 1924 discovery: cancer cells prefer aerobic glycolysis (the Warburg effect) even when oxygen is available. He argues the root cause is mitochondrial dysfunction. Damaged mitochondria can’t perform efficient oxidative phosphorylation (OXPHOS), so cancer cells ferment glucose and glutamine for energy.

Seyfried’s Solution: The Press-Pulse Strategy

  • Press: Calorie-restricted ketogenic diet + glucose control to starve fermentation.
  • Pulse: Glutamine-targeting agents (e.g., DON) and other metabolic drugs.

This approach has shown promise in highly glycolytic cancers like glioblastoma. Normal cells adapt to ketones; cancer cells (in theory) cannot. You can find more details on these mechanisms via Springer.

Strengths Praised by Jane McLelland:

  • Legitimized metabolic oncology when genetics dominated.
  • Emphasized non-toxic, accessible interventions.
  • Highlighted glutamine fermentation as the “missing link.”


The Blind Spot Jane McLelland Exposes: Not All Cancers Are Glycolytic

Here’s the game-changing insight from McLelland’s article: Many common cancers are OXPHOS-dominant. Their mitochondria are not broken—they’re hyperactive, driving growth via oxidative phosphorylation, fatty-acid oxidation, and the Krebs cycle.

Examples of OXPHOS-Dominant Cancers Include:

  • ER+ (Luminal A/B) breast cancer (~70% of cases)
  • Prostate cancer
  • Certain lymphomas
  • Chromophobe renal cell carcinoma

Why This Matters for Patients:

These tumors often show low FDG-PET avidity (they don’t guzzle glucose). A strict ketogenic diet cancer protocol can backfire by flooding them with ketones and fatty acids—the exact fuels they love. McLelland calls this the “inversion problem.”

Warning: Blindly following Seyfried-inspired protocols without tumor phenotyping risks feeding the cancer instead of starving it.

For deeper insights into precision metabolic care, clinicians point to platforms like Precision Wellbeing.

Jane McLelland’s Metro Map: The Personalized Solution

McLelland doesn’t reject Seyfried—she builds on him. Her Metro Map framework maps every tumor’s unique fuel sources, signaling pathways, and vulnerabilities.

For OXPHOS cancer types, the goal is to target the mitochondria directly using targeted interventions:

  • Metformin: Complex I inhibitor.
  • Statins: Disrupt the mevalonate pathway and CoQ10.
  • Atovaquone: Complex III inhibitor.
  • Tigecycline / Doxycycline: Mitochondrial protein synthesis inhibitors.

She shares a hypothetical ER+ breast cancer case where strict keto + glucose control (without metformin or statins) potentially accelerated disease by supplying alternative fuels.

Key Takeaway: Phenotype first. One-size-fits-all keto works brilliantly for some tumors and can harm others.

Metabolic Theory of Cancer: Metro Map by Jane McLelland

Evidence Supporting McLelland’s View

Recent studies back her concerns regarding the oversimplification of the Tom Seyfried cancer theory:

  • CRISPR screens and preclinical data show ER+ breast cancer persister cells rely heavily on OXPHOS.
  • Research in Cancer Research, eLife, and Oncotarget highlights mitochondrial vulnerabilities in endocrine-resistant breast cancers.
  • Seyfried’s own work acknowledges residual mitochondrial function, but the popular interpretation in patient communities often oversimplifies it as “all cancers have broken mitochondria.”

Practical Advice for Patients and Clinicians (2026 Edition)

  1. Get a Metabolic Profile: Ask for FDG-PET, glutamine PET (where available), or advanced metabolomics.
  2. Match Therapy to Tumor Fuel: Glycolytic? Lean into Seyfried’s press-pulse. OXPHOS-dominant? Add mitochondrial inhibitors per McLelland’s Metro Map.
  3. Never Go Keto Alone: Combine with repurposed drugs and continuous monitoring (continuous glucose monitors + ketone testing).
  4. Work with Experts: Seek clinicians familiar with both Seyfried and McLelland approaches.
  5. Monitor Closely: Track tumor markers, imaging, and symptoms every 4–6 weeks during metabolic shifts.

Warning: Metabolic therapies remain adjunctive/experimental. Always integrate with standard care under medical supervision.

Potential Risks of the “Keto-for-Everyone” Narrative

Online communities often present Seyfried’s work as universal. McLelland’s article is a timely reality check, highlighting risks such as:

  • Cachexia risk in already frail patients.
  • Nutrient deficiencies from extreme restriction.
  • False hope if the tumor type doesn’t match the protocol.

Thoughtful critiques like hers prevent well-intentioned mistakes and help patients learn how to safely starve cancer.

Conclusion: The Future of Metabolic Oncology Is Personalized

Jane McLelland’s “Beyond Warburg” piece doesn’t diminish Tom Seyfried—it elevates the entire field by demanding nuance. Cancer metabolism is far more complex than any single map (Warburg, Seyfried, or Metro) can fully capture.

The winning strategy in 2026? Honor Seyfried’s foundational work while using McLelland’s Metro Map to tailor interventions to the actual tumor biology in front of you.

If you’re navigating a cancer diagnosis or supporting someone who is, read McLelland’s original Substack immediately. Then phenotype your tumor and build a truly personalized metabolic plan.

FAQ – Tom Seyfried Cancer Theory & Jane McLelland Critique

Q: Does Tom Seyfried say all cancers are glycolytic?

A: He emphasizes mitochondrial dysfunction leading to fermentation across most cancers, but acknowledges heterogeneity. Popular interpretations in online forums can often oversimplify this nuanced point.

Q: Is the ketogenic diet bad for breast cancer?

A: It depends heavily on the subtype. Highly glycolytic triple-negative breast cancer may benefit; however, OXPHOS-dominant ER+ often needs targeted mitochondrial inhibitors alongside dietary adjustments.

Q: What is Jane McLelland’s Metro Map?

A: It is a visual framework mapping cancer’s diverse fuel sources (glucose, glutamine, fatty acids, etc.) and matching them to specific repurposed drugs and supplements to systematically block those pathways.

Q: Should I follow Seyfried or McLelland?

A: Ideally, both. Use Seyfried’s brilliant press-pulse foundation and layered implementation, combined with McLelland’s phenotyping framework for absolute precision.

Q: Where can I read the original article?

A: You can read the full piece titled "Beyond Warburg: What Tom Seyfried Gets Right — And the Blind Spot That Could Cost Your Patient" on the official How to Starve Cancer Substack.


Related: Metabolic Oncology 2026: The Definitive Evidence-Based Framework Integrating Cancer Metabolism, Immunotherapy, Precision Oncology, and Personalized Treatment Strategies


Disclaimer: This article is for informational purposes only and is not medical advice. Consult qualified healthcare professionals before making any treatment decisions.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

Fenbendazole and Ivermectin for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

By Editorial Team
Image
Summary Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited effective therapies and poor survival, especially in stage 4 disease. Repurposing antiparasitic agents such as fenbendazole and ivermectin has garnered interest due to their demonstrated anti-cancer properties in preclinical studies. Methods: We reviewed and synthesized 35 detailed case reports from 2022 to 2026 documenting the clinical use of fenbendazole and ivermectin, alone or in combination with standard therapies, in patients with advanced pancreatic cancer. Tumor markers, imaging outcomes, and clinical responses were analyzed alongside mechanistic literature. Results: Across cases, patients exhibited marked reductions in CA19-9 tumor markers (often >70%), significant tumor shrinkage on imaging, and improved clinical status. Responses were observed even in chemotherapy-resistant and metastatic disease. Mechanistic studies support multiple anti-cancer effects of...
Read more